Saturday 17 October 2026
Export COCH’s income statement to Excel — free account
Envoy Medical, Inc.
COCH Healthcare Medical Devices
Envoy Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $241,000.00, up 7.11% from fiscal 2024. In the quarter to June 2026, revenue fell 34.6%, EPS grew 78.1% and free cash flow fell 22.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.67
0.03
+4.69%
Follow COCH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
81.95 | 63.70 | 197.38 | 397.06 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.94) | (2.70) | (7.62) | (15.06) | |
P/B ratio |
0.00 | 0.00 | 4.55 | 24.88 | |
Price to Tangible BV |
0.00 | 0.00 | 4.55 | 24.88 | |
EV/Sales |
212.07 | 175.25 | 220.33 | 449.92 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.51) | (2.32) | (2.51) | (4.33) | |
EV/FCF |
(2.58) | (2.30) | (2.49) | (4.29) | |
Quick Ratio |
0.40 | 0.33 | 2.07 | 1.56 | |
Current Ratio |
0.64 | 0.54 | 2.27 | 1.73 | |
Net Debt/EBITDA |
0.66 | 0.62 | 4.46 | 3.74 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.02 | 0.01 | 0.01 | |
Operating CF/Net income |
0.56 | 0.73 | 1.06 | 0.75 | |
Capex/Depreciation |
0.00 | (0.56) | 0.00 | (0.02) | |
Interest Coverage |
(12.12) | — | — | — | |
Research and Development Expense of Revenue |
6,428.57% | 6,070.67% | 9,338.46% | 6,141.18% | |
Selling, General and Administrative Expense of Revenue |
6,778.57% | 2,261.33% | 5,238.46% | 4,333.33% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
771.43% | 153.33% | 725.64% | 482.35% | |
Graham Net Nets |
(0.59) | (0.94) | 0.17 | 0.02 | |
Graham Number |
3.34 | 3.79 | 0.00 | 0.00 | |
Earnings Yield |
(180.77%) | (184.85%) | (150.75%) | (96.20%) | |
Free Cash Flow Yield |
(100.21%) | (119.73%) | (44.85%) | (26.42%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.20) | (0.24) | (0.09) | (0.05) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.20) | (0.25) | (0.09) | (0.05) | |
Cash per Share |
0.16 | 0.16 | 0.37 | 0.19 | |
Shareholders Equity per Share |
(0.35) | (0.52) | 0.15 | 0.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.35) | (0.52) | 0.15 | 0.03 | |
Free Cash Flow |
(4.33) | (5.86) | (6.06) | (5.46) | |
Working Capital |
(3.23) | (5.28) | 15.47 | 9.28 | |
Capital Expenditures |
0.00 | (0.17) | — | (0.01) | |
Net Current Asset Value |
(10.08) | (14.44) | 8.02 | 1.27 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 2.29 | 0.00 | 0.12 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.14 | 0.44 | 0.06 | 0.06 | |
Average Payables |
2.22 | 2.29 | 1.68 | 1.83 | |
Average Inventory |
1.64 | 1.63 | 1.57 | 1.58 | |
Average Assets |
8.79 | 10.05 | 20.10 | 16.92 | |
Average Common Equity |
(13.09) | (15.50) | (7.03) | (13.28) |
Columns are period end dates